Selective HSP90β Inhibition Disrupts SREBP1-Associated Metabolic Signaling and Suppresses Ovarian Cancer Progression: A Pilot Study
International Journal of Molecular Sciences · 20.11.2026 · 27 (22) · 10460
DOI: 10.3390/ijms272210460 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.11.2026. Verfasst von Wanrui Wang und 14 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP), Ovarian Cancer Research Program, National Institutes of Health (NIH), National Cancer Institute, Walther Cancer Foundation.
Abstract (Originalsprache)
Ovarian cancer progression is supported by metabolic interactions between tumor cells and the adipocyte-rich peritoneal microenvironment, which can be further altered by obesity. Sterol regulatory element-binding protein 1 (SREBP1), a master regulator of lipid metabolism, represents a potential therapeutic target in this setting. Because heat shock protein 90 (HSP90) regulates SREBP1 stability and processing, we investigated whether selective inhibition of HSP90β with NDNB25 could disrupt SREBP1-associated metabolic signaling and suppress ovarian cancer progression. In a diet-induced obesity model, NDNB25 significantly reduced overall tumor burden in both low-fat and high-fat diet mice and decreased adipocyte area within intra-tumoral, peri-tumoral, and surrounding visceral adipose regions. In human and murine ovarian cancer cells, NDNB25 altered SREBP1 protein abundance and produced concentration-dependent effects on cell viability. Transcriptomic analysis demonstrated negative enrichment of an SREBP1-associated lipogenic program across OVCAR5, OVCAR8, and ID8 cells, together with broader remodeling of lipid-metabolic, inflammatory, and tumor-associated signaling pathways. Analysis of gene expression data from human ovarian tumors further demonstrated a positive association between HSP90AB1 expression and SREBP1-associated lipogenic signaling. Collectively, these findings demonstrate that selective HSP90β inhibition suppresses ovarian cancer progression across lean and obese host environments and induces broad transcriptional remodeling of metabolic and tumor-associated pathways, including SREBP1-associated lipid metabolism, supporting HSP90β as a potential therapeutic target for metabolically adapted ovarian cancer.
Förderung
- Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP), Ovarian Cancer Research Program
- National Institutes of Health (NIH), National Cancer Institute
- Walther Cancer Foundation
- Harper Cancer Research Institute
Zitieren
APA
Wang, W., Strasiotto, B., Cronberger, E., Wikenheiser, G., Crotzer, E., Breslin, C., Yang, J., Oh, M., Kerker, T., Dominique, G. M., Johnson, J., D’Amico, T., Mishra, S., Blagg, B. S. J., & Stack, M. S. (2026). Selective HSP90β Inhibition Disrupts SREBP1-Associated Metabolic Signaling and Suppresses Ovarian Cancer Progression: A Pilot Study. International Journal of Molecular Sciences, 27(22), 10460. https://doi.org/10.3390/ijms272210460
Vancouver
Wang W, Strasiotto B, Cronberger E, Wikenheiser G, Crotzer E, Breslin C, et al. Selective HSP90β Inhibition Disrupts SREBP1-Associated Metabolic Signaling and Suppresses Ovarian Cancer Progression: A Pilot Study. International Journal of Molecular Sciences. 2026;27(22):10460. doi:10.3390/ijms272210460
BibTeX
@article{Wang2026,
author = {Wang, Wanrui and Strasiotto, Brighton and Cronberger, Emily and Wikenheiser, Grace and Crotzer, Ellen and Breslin, Caitlyn and Yang, Jing and Oh, Maia and Kerker, Theresa and Dominique, Gena M. and Johnson, Jeffrey and D’Amico, Terin and Mishra, Sanket and Blagg, Brain S. J. and Stack, M. Sharon},
title = {Selective HSP90β Inhibition Disrupts SREBP1-Associated Metabolic Signaling and Suppresses Ovarian Cancer Progression: A Pilot Study},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {22},
pages = {10460},
doi = {10.3390/ijms272210460}
}
EUVIMED